Login to Your Account



Other News To Note


Wednesday, January 23, 2013
• Molecular Partners AG, of Zurich, Swizterland, said results from a Phase I/II study published in the American Journal of Ophthalmology showed that MP0112, a long-acting anti-VEGF DARPin, was found to be safe in patients with diabetic macular edema and showed suppression of VEGF-A concentrations in aqueous humor after a single intraocular injection, with a pharmacokinetic half-life of about two weeks.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription